NCT03384693View on ClinicalTrials.gov

Defibrotide TMA Prophylaxis Pilot Trial

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

May 1, 2018

Primary Completion Date

July 31, 2020

Study Completion Date

July 31, 2020

Conditions
Thrombotic Microangiopathies
Interventions
DRUG

Defibrotide

Defibrotide is an anticoagulant and fibrinolytic agent that has been shown to be an effective treatment in other endothelial disorders such as hepatic veno-occlusive disease.

Trial Locations (1)

94143

Benioff Children's Hospital at UCSF Medical Center, San Francisco

All Listed Sponsors
lead

University of California, San Francisco

OTHER

NCT03384693 - Defibrotide TMA Prophylaxis Pilot Trial | Biotech Hunter | Biotech Hunter